Chest Medicine
In patients hospitalized with COVID-19, right ventricular dilation or dysfunction was independently associated with a >2-fold increase in risk for mortality
10 Nov, 2020 | 09:36h | UTCCommentaries: Utility of RV Remodeling Over Risk Stratification in COVID-19 – American College of Cardiology AND Damage to heart’s right ventricle predicts a greater chance of death from COVID-19 – Weill Cornell Medical College
Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
10 Nov, 2020 | 09:35h | UTCCommentary: Aspirin to be tested as potential COVID-19 drug in UK study – Reuters
Current and evolving standards of care for patients with acute respiratory distress syndrome (ARDS). Definition, ventilatory support, fluid management, use of corticosteroids, indications of prone positioning and ECMO, and more.
10 Nov, 2020 | 09:26h | UTCCurrent and evolving standards of care for patients with ARDS – Annals of Intensive Care
Commentary on Twitter
#ARDS current & evolving standards of care
➡️ definition 10y after Berlin
➡️ MV: P/volume limits; PEEP & recruitment; spontaneous breathing
➡️ adjuncts: proning; NMBAs; iNO; #ECMO
➡️ pharmacotherapy: steroids; fluids; specific agents
➡️ #COVID19#FOAMcc https://t.co/rXGsAs2M4D pic.twitter.com/6FRWXtBiME— Intensive Care Medicine (@yourICM) November 7, 2020
JACC Focus Seminar: Advanced management of intermediate- and high-risk pulmonary embolism. Patients who deteriorate despite anticoagulation and those with high-risk PE should be considered for advanced therapies for pulmonary reperfusion, including systemic fibrinolysis, surgical embolectomy, and catheter-based therapies
9 Nov, 2020 | 01:20h | UTCAdvanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar – Journal of the American College of Cardiology (free for a limited period)
Podcast: Advanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar
High prevalence of pericardial involvement in college student-athletes recovering from COVID-19
5 Nov, 2020 | 09:08h | UTC
Commentary on Twitter
The heart and #COVID19 in 54 consecutive college athletes @WVUHealth w/ echo, MRIhttps://t.co/76DvMNaeBL @JACCJournals todayhttps://t.co/hMyY8cQNln @ppsengupta1 @BritoCardio
>1/3 had resolving pericarditis with mild-moderate covid or no symptoms; no myocarditis, no controls pic.twitter.com/GTj3JZxL26— Eric Topol (@EricTopol) November 5, 2020
Postmortem lungs of COVID-19 patients show massive damage
5 Nov, 2020 | 09:06h | UTCPostmortem lungs of COVID-19 patients show massive damage- CIDRAP
Original article: Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology – EBioMedicine
Review: Diagnosis and treatment of lower extremity venous thromboembolism. Role of pretest probability and D-Dimer on diagnosis + treatment issues such as postthrombotic syndrome and the role of new anticoagulants
5 Nov, 2020 | 09:00h | UTCDiagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review – JAMA (free for a limited period)
Summary: Diagnosis and Treatment of Lower Extremity Venous Thromboembolism – American College of Cardiology
Review of clinical strategies for implementing lung and diaphragm-protective ventilation: avoiding insufficient and excessive effort
5 Nov, 2020 | 08:46h | UTC
Commentary on Twitter
Protecting lung (vs excessive stress/strain) & diaphragm (vs atrophy/injury due to low/excessive efforts) bedside:
➡️ inspiratory/expiratory MV settings
➡️ monitoring & managing effort or drive
➡️ managing dyssynchrony
➡️ sedation
➡️ adjuvant strategieshttps://t.co/pdvKndwHYY pic.twitter.com/irvrX9WxTj— Intensive Care Medicine (@yourICM) November 2, 2020
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Dosage, timing of initiation, mode of administration, duration of therapy, infection surveillance, tapering, and more
5 Nov, 2020 | 08:45h | UTC
Commentary on Twitter
Glucocorticoids in #ARDS… focus not only on molecule! Key elements to achieve optimal response to therapy:
➡️ dosage (initial, overtime, adjustments)
➡️ timing of initiation
➡️ mode of administration
➡️ duration of therapy
➡️ tapering
➡️ co-interventionshttps://t.co/4b9vtNXsb7 pic.twitter.com/X6UZyMSI1r— Intensive Care Medicine (@yourICM) November 4, 2020
New CDC Report found that pregnant women with Covid-19 are more likely to have severe illness
4 Nov, 2020 | 09:47h | UTCCommentary: Pregnant women with Covid-19 face higher risk of severe illness and death, study says – CNN
Clinical strategies for implementing lung and diaphragm-protective ventilation: avoiding insufficient and excessive effort
4 Nov, 2020 | 09:19h | UTC
Commentary on Twitter
Protecting lung (vs excessive stress/strain) & diaphragm (vs atrophy/injury due to low/excessive efforts) bedside:
➡️ inspiratory/expiratory MV settings
➡️ monitoring & managing effort or drive
➡️ managing dyssynchrony
➡️ sedation
➡️ adjuvant strategieshttps://t.co/pdvKndwHYY pic.twitter.com/irvrX9WxTj— Intensive Care Medicine (@yourICM) November 2, 2020
Updated clinical guide for the critical care management of adults with COVID-19
3 Nov, 2020 | 03:18h | UTC
Spike in prescribing dexamethasone to Covid-19 patients may do more harm than good
3 Nov, 2020 | 03:11h | UTCSpike in prescribing dexamethasone to Covid-19 patients may do more harm than good – STAT
Perspective: A series of disappointing results of immune-based therapies for COVID-19
3 Nov, 2020 | 03:13h | UTCA Series of Disappointing Results of Immune-Based Therapies for COVID-19 – HIV and ID Observations
Opinion – Hydroxychloroquine: A tale of overzealous optimism and patient harm
3 Nov, 2020 | 03:09h | UTCHydroxychloroquine: A tale of overzealous optimism and patient harm – First10EM
Regeneron: Independent committee recommends holding trial enrollment in hospitalized patients with high oxygen requirements
2 Nov, 2020 | 02:31h | UTC
Commentary on Twitter
More potential evidence against antibody drugs late in course of #COVID19: Regeneron says independent cmte has recommended not enrolling pts on high oxygen into trial "based on a potential safety signal and an unfavorable risk/benefit profile at this time" https://t.co/moHtuhV9cP
— Meg Tirrell (@megtirrell) October 30, 2020
CDC Report: Transmission of SARS-COV-2 infections in households
2 Nov, 2020 | 02:37h | UTCCommentaries: A new CDC study suggests roughly 50% of people living with someone who has COVID-19 get it — usually in less than 5 days – Business Insider AND Household spread of Covid-19 is common and quick, a new CDC study finds – CNN
Commentaries on Twitter
New CDC study finds that children pass along Covid to household members just as frequently as adults do. This underscores why it's crucial to contain the virus among all populations. https://t.co/sZHOh1wOG3
— Dr. Tom Frieden (@DrTomFrieden) October 31, 2020
(1/7) Important prospective study of household transmission by CDC, suggesting children and adults are similarly likely to transmit #SARSCoV2. The household secondary attack rate was at least 35%, and 18% of cases were asymptomatic.https://t.co/iEdx2VBPXz pic.twitter.com/mq4LxSoU0J
— Dr Zoë Hyde (@DrZoeHyde) October 31, 2020
Report: COVID-19 infection fatality ratio estimates from seroprevalence
30 Oct, 2020 | 01:16h | UTCFull report: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence
Commentary on Twitter
UPDATE #COVID19 Infection Fatality Ratio (IFR):
➡️1.15% IFR (high income countries)
➡️0.23% IFR (low income countries)
➡️0.1% IFR (under 40 year olds)
➡️5.6% IFR (over 80 year olds)
➡️Risk of COVID19 death doubles every eight years of age👇Report 34 https://t.co/171hx5LMvp pic.twitter.com/M1rmq673Rf
— MRC Centre for Global Infectious Disease Analysis (@MRC_Outbreak) October 29, 2020
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
30 Oct, 2020 | 01:14h | UTCThe ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science
Commentaries on Twitter
Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG
— Jon Cohen (@sciencecohen) October 28, 2020
Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5— Eric Topol (@EricTopol) October 28, 2020
Videos in clinical medicine: Percutaneous Tracheostomy
30 Oct, 2020 | 01:05h | UTCPercutaneous Tracheostomy – New England Journal of Medicine
Randomized phase 2 trial: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
29 Oct, 2020 | 09:16h | UTCAudio Interview: A New Monoclonal Antibody for Covid-19 – New England Journal of Medicine
Commentaries on Twitter
BLAZE-1🔥 – outpatient trial of LY-Cov555, mAb recently dropped from ACTIV-3 inpatient trial
Only 1 of the 3 mAb dosages (middle one 🤷♂️) ⬇️ VL by d11
mAb assoc with modest ⬇️ in healthcare visits (1.6% vs 6.3% for placebo)
😑 Far from a game changerhttps://t.co/zZMGlodaaF pic.twitter.com/ofs1UgN1ZA
— Ilan Schwartz is on🦋 (@GermHunterMD) October 28, 2020
Phase 2 Lilly #SARSCoV2 monoclonal antibody outpatient trial just published @NEJM
The lack of a dose response for viral load reduction +modest effects on symptoms do not make this look like a potent intervention https://t.co/oyRG8fUNHf pic.twitter.com/uobuCIznmD— Eric Topol (@EricTopol) October 28, 2020
Video: Coronavirus update with Anthony Fauci – October 28, 2020
29 Oct, 2020 | 09:11h | UTCCoronavirus Update With Anthony Fauci – October 28, 2020 – JAMA
Clinical practice: Mild or moderate Covid-19
29 Oct, 2020 | 09:12h | UTCMild or Moderate Covid-19 – New England Journal of Medicine
Randomized trial: Osimertinib in resected EGFR-Mutated non–small-cell lung cancer
29 Oct, 2020 | 09:04h | UTCOsimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine
Ten tips to optimize weaning and extubation success in the critically ill
29 Oct, 2020 | 08:50h | UTCTen tips to optimize weaning and extubation success in the critically ill – Intensive Care Medicine
Commentary on Twitter
Wean/extubate critically ills
1⃣optimize (⬇️) sedation
2⃣diaphragm-protective MV
3⃣daily screen for SBT
4⃣best SBT?
5⃣weaning strategy
6⃣what if SBT fails
7⃣muscle load/efficiency ratio
8⃣weaning/extubation failure
9⃣post-extubation support
🔟 tracheostomyhttps://t.co/TaYdzMvisK pic.twitter.com/q9qQOVKioZ— Intensive Care Medicine (@yourICM) October 27, 2020


